Patient Case 1: Navigating the Decision to Switch Treatments

Experts describe how deciding when to switch therapies is a nuanced, case-by-case decision based on patient dialogue and clinical judgment. Key considerations include whether the residual psoriasis is in high-impact areas like the face or genitals, which disproportionately affect quality of life despite low Body Surface Area (BSA). The financial and logistical burdens of alternatives like phototherapy or multiple topicals also inform the choice.

Experts stress that the most costly switch is initiating a new biologic due to loading doses and prior authorization hurdles. Therefore, they prefer a targeted plan over a trial-and-error approach. Effective communication involves asking specific questions about burden in intimacy, work, and daily activities.